HCM
OACC

Highbridge Capital Management’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Highbridge Capital Management’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-450,000
Closed -$4.5M – 304
2024
Q4 		$4.5M Buy
+450,000
New +$4.49M 0.17% 91

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return

Highbridge Capital Management's OACC Position: Q1 2025 in Review

Highbridge Capital Management sold out of Oaktree Acquisition Corp III Life Sciences (OACC) in Q1 2025, closing a stake of 450,000 shares — an estimated $4.5M sold.

Highbridge Capital Management first reported a position in OACC in Q4 2024 and held it in 1 quarter. The position peaked at $4.5M in Q4 2024. 39 funds tracked by Wall St. Rank hold OACC as of Q1 2025.

  • Highbridge Capital Management reported no remaining Oaktree Acquisition Corp III Life Sciences position as of Q1 2025 after selling out during the quarter.
  • Highbridge Capital Management sold 450,000 Oaktree Acquisition Corp III Life Sciences shares in Q1 2025, an estimated $4.5M.
  • Highbridge Capital Management first reported a position in Oaktree Acquisition Corp III Life Sciences in Q4 2024 and held it in 1 quarter.
  • Highbridge Capital Management's Oaktree Acquisition Corp III Life Sciences position peaked at $4.5M in Q4 2024.
  • 39 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q1 2025.

Based on Highbridge Capital Management's 13F filing for Q1 2025, filed 12 May 2025.